Australia's most trusted
source of pharma news
Tuesday, 17 September 2024
Posted 3 September 2024 AM
Keen to keep protection for its blockbuster Stelara, Janssen is using a highly unusual patent strategy that, if successful, could extend protection for the drug until 2027.
The company is also seeking a standard patent which could push out protection for Stelara over an even longer timeframe - with an expiry in 2039.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.